Imidazole compounds substituted with a six or seven membered...

Details Imidazole compounds substituted with a six or seven membered... Imidazole compounds substituted with a six or seven membered...

1999-03-08

2001-04-03

Bernhardt, Emily (Department: 1611)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S254050, C514S218000, C540S575000, C544S364000, C544S370000, C544S337000

Reexamination Certificate

active

06211182

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to C- or N-(imidazolylalkyl) substituted cyclic amine compounds having valuable pharmacological properties, especially central nervous system (“CNS”) activities and activity against inflammatory disease and allergic conditions. Compounds of this invention are agonists or antagonists of the histamine-H
3
receptor.
BACKGROUND OF THE INVENTION
H
3
receptor sites are known and are of current interest to those skilled in the art as a therapeutic target. U.S. Pat. No. 4,767,778 (Arrang et al) discloses certain imidazoles that behave as agonists of the H
3
receptors in rat brain. European Patent Application No. 0 420 396 A2 (Smith Kline & French Laboratories Limited) and Howson et al., (
Bioorg.
&
Med. Chem. Letters
, (1992), Vol. 2 No. 1, pp. 77-78) describe imidazole derivatives having an amidine group as H
3
agonists. Van der Groot et al. (
Eur. J. Med. Chem
. (1992) Vol. 27, pp. 511-517) describe isothiourea analogs of histamine as potent agonists or antagonists of the histamine-H
3
receptor, and these isothiourea analogs of histamine overlap in part with those of the two references cited above. Clapham et al. [“Ability of Histamine-H
3
Receptor Antagonists to Improve Cognition and to Increase Acetylcholine Release in vivo in the Rat”,
British Assn. for Psychopharmacology,
Jul. 25-28 (1993), reported in
J. Psychopharmacol
. (Abstr. Book), A17] describe the ability of histamine-H
3
receptor antagonists to improve cognition and to increase release of acetylcholine in vivo in the rat. Clapham et al. [“Ability of the selective Histamine-H
3
Receptor Antagonist Thioperamide to improve Short-term Memory and Reversal Learning in the Rat”,
Brit. J. Pharm. Suppl.,
1993, 110, Abstract 65P] present results showing that thioperamide can improve short-term memory and reversal learning in the rat and implicate the involvement of H
3
receptors in the modulation of cognitive function. Yokoyama et al. [“Effect of Thioperamide, a Histamine-H
3
Receptor Antagonist, on —Electrically Induced Convulsions in Mice”,
Eur. J. Pharmacol
., (1993), Vol. 234, pp. 129-133] report how thioperamide decreased the duration of each phase of convulsion and raised the electroconvulsive threshold, and go on to suggest that these and other findings support the hypothesis that the central histaminergic system is involved in the inhibition of seizures. International Patent Publication No. WO 9301812-Al (SmithKline Beecham PLC) describes the use of S-[3-(4(5)-imidazolyl)propyl]isothiourea as a histamine-H
3
antagonist, especially for treating cognitive disorders, e.g. Alzheimer's disease and age-related memory impairment. Schlicker et al. [“Novel Histamine-H
3
Receptor Antagonists: Affinities in an H
3
Receptor Binding Assay and Potencies in Two Functional H
3
Receptor Models”,
British J. Pharmacol
., (1994), Vol. 112, 1043-1048] describe a number of imidazolylalkyl compounds wherein the imidazolylalkyl group is bonded to a guanidine group, an ester group, an amide group, a thioamide group and a urea group, and compared these to thioperamide. Leurs et al. [“The Histamine-H
3
-receptor: A Target for Developing New Drugs”,
Progr. Drug Res
. (1992), Vol. 39, pp. 127-165] and Lipp et al. [“Pharmacochemistry of H
3
-receptors” in
The Histamine Receptor
, eds.: Schwartz and Haas, Wiley-Liss, New York (1992), pp. 57-72] review a variety of synthetic H
3
receptor antagonists, and Lipp et al. (ibid.) have proposed the necessary structural requirements for an H
3
receptor antagonist.
WO 95/14007 claims H
3
receptor antagonists of the formula
wherein A, m, n, R
1
and R
2
are defined therein. The compounds are disclosed as being useful for treating various disorders, in particular such caused by allergy-induced responses.
WO 93/12093 discloses imidazolylmethyl piperazines and diazepines as H
3
antagonists. U.S. patent application, Ser. No. 08/965,754, filed Nov. 7, 1997, discloses imidazolylalkyl substituted heterocyclic ring compounds as H
3
receptor antagonists. U.S. patent application, Ser. No. 08/966,344, filed Nov. 7, 1997, discloses phenylalkylimidazoles as H
3
receptor antagonists.
Reference is also made to U.S. application, Ser. No. 08/689,951, filed Aug. 16, 1996 which claims the combined use of a histamine-H, receptor antagonist and a histamine-H
3
receptor antagonist for treatment of allergy-induced airway responses.
Reference is also made to J. R. Bagley et al,
Journal of Medicinal Chemistry
, (1991), Vol. 34, 827-841, which discloses, among others, N-(imidazolylalkyl) substituted cyclic amine compounds useful as analgesics such as the amine compound with the formula:
Pending U.S. patent application, Ser. No. 09/173,642, filed Oct. 16, 1998 (R. Wolin et al), discloses N-(imidazolylalkyl) substituted cyclic amine compounds having H
3
antagonist activity.
In view of the art's interest in compounds which affect the H
3
receptor, novel compounds having agonist or antagonist activity on H
3
receptors would be a welcome contribution to the art. This invention provides just such a contribution by providing novel compounds having H
3
agonist or antagonist activity.
SUMMARY OF THE INVENTION
This invention provides novel compounds with H
3
receptor agonist or antagonist activity with the inventive compound having the general formula depicted in Formula I, including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compounds:
wherein G is a spacer moiety selected from the group consisting of C
1
-C
7
alkyl, C
2
-C
7
alkenyl, C
2
-C
7
alkynyl, C
1
-C
7
alkyl-NHCO—, and —SO2—, with said alkyl, alkenyl or alkynyl being optionally substituted with one or more groups selected from substituted or unsubstituted alkyl, aryl, aralkyl, alkylaryl, —O—alkyl, and -CO
2
-alkyl, and wherein said substituents are selected from the group consisting of alkyl, aryl, aralkyl, and halogen; and
T is a six-membered ring or a seven-membered ring containing two ring nitrogens and belonging to the formula a shown below, with said T ring being connected to said G moiety at either a ring carbon atom of ring T or a ring nitrogen atom of ring T:
wherein n is 1 or 2; and
R
2
, R
3
, R
4
, R
5
, R
6
and R
7
can be the same or different with the proviso that no two of said R
3
, R
4
, R
5
and R
6
can be bound to the same carbon atom of ring T except when at least one of said R
3
, R
4
, R
5
and R
6
is H,
wherein said R
2
, and R
7
are independently selected from the group consisting of H, substituted or unsubstituted C
1
-C
6
alkyl, substituted or unsubstituted C
2
-C
6
alkenyl, substituted or unsubstituted C
2
-C
6
alkynyl, aryl, aralkyl, alkylaryl, —C(═O)R
8
, —CO
2
R
8
, —SO
2
R
8
, S(O)R
8
, —C(O)NR
8
R
9
, and —C(=NR
8
)NR
8
R
9
,
and said R
3
, R
4
, R
5
, and R
6
can be the same or different and are independently selected from the group consisting of H, substituted or unsubstituted C
1
-C
6
alkyl, substituted or unsubstituted C
2
-C
6
alkenyl, substituted or unsubstituted C
2
-C
6
alkynyl, aryl, aralkyl, alkylaryl, —C(═O)R
8
, —CO
2
R
8
, —SO
2
R
8
, S(O)R
8
, —C(O)NR
8
R
9
, —C(═NR
8
)NR
8
R
9
, —C—O—R
8
, —OC(O)R
8
, —N(R
8
)
2
, —NR
8
R
9
, —SR
8
, —OH, —OR
8
, —CH
2
OR
8
, —CH
2
N(R
8
)
2
, —CH
2
SR
8
, —NR
8
(CO)NR
8
R
9
, —CX(R
8
)
2
, —CX
2
R
8
, CX
3
, —OCX
3
, —N(R
8
)—S(O)R
9
, —N(R
8
)—SO
2
R
9
, (═O), (═N—OR
8
), —NR
8
—SO
2
—NR
8
R
9
, —SO
3
H, and —PO
3
H
2
, wherein R
8
and R
9
are independently H or substituted or unsubstituted C
1
-C
6
alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkenylaryl, substituted or unsubstituted alkenyl, heteroaryl and X is a halogen, further wherein when the spacer moiety G is linked to a ring nitrogen atom of ring T then one of said R
2
or R
7
is absent on the ring nitrogen atom linked to the G moiety and the other of

Affiliated with

Also associated with

Rating

Imidazole compounds substituted with a six or seven membered... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazole compounds substituted with a six or seven membered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazole compounds substituted with a six or seven membered... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2515349